-Provides Vertex with leading gene editing capabilities to develop
novel therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy
Type 1-
-CRISPR to receive an upfront payment of $175 million, with potential
for additional milestone and royalty payments-
-Exonics to be acquired for an upfront payment of $245 million, with
potential for additional milestone payments-
-John T. Gray, Ph.D. appointed Vertex Senior Vice President, Genetic
Therapies-
BOSTON & WATERTOWN, Mass. & ZUG, Switzerland–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that
the company is enhancing its gene editing capabilities to develop novel
therapies for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy
Type 1 (DM1) by expanding its collaboration with CRISPR Therapeutics and
acquiring Exonics Therapeutics.
Vertex and CRISPR Therapeutics (NASDAQ: CRSP) have expanded their
collaboration and entered into an exclusive licensing agreement to
discover and develop gene editing therapies for the treatment of DMD and
DM1.
Vertex and Exonics Therapeutics have entered into a definitive agreement
under which Vertex will acquire privately held Exonics, a company
focused on creating transformative gene editing therapies to repair
mutations that cause DMD and other severe neuromuscular diseases.
“Through the expanded collaboration with CRISPR and the acquisition of
Exonics, we are bringing together the intellectual property,
technologies, and scientific expertise needed to establish a leading
gene editing platform for DMD and DM1. These transactions are highly
aligned with our strategy of investing in scientific innovation to
create transformative medicines for people with serious diseases,” said
Jeffrey Leiden, M.D., Ph.D., Chairman, President and Chief Executive
Officer of Vertex. “We are continuing to build a toolbox of small
molecule and nucleic acid technologies and capabilities that will allow
us to drive scientific innovation to produce transformative medicines
for a broad portfolio of diseases.”
“This agreement with Vertex reflects the strong collaboration we have
built together in other programs and underscores Vertex’s commitment to
gene editing,” said Samarth Kulkarni, Ph.D., Chief Executive Officer of
CRISPR Therapeutics. “We continue to make significant advancements in
enabling in vivo approaches for gene editing and are excited about the
possibility of developing potentially curative therapies for DMD and DM1
together with Vertex.”
“DMD and DM1 are devastating muscle diseases with no curative therapies
available,” said Eric Olson, Ph.D., Founder and Chief Science Advisor of
Exonics, and Professor and Chair of the Department of Molecular Biology
at UT Southwestern Medical Center. “Vertex has a proven track record of
developing important therapies for serious diseases and we are excited
to combine our efforts to potentially develop a safe and efficacious
one-time treatment for severe neuromuscular diseases.”
“The Duchenne community needs novel approaches to treat and cure this
devastating disease and Exonics’ technology has the potential to
dramatically improve the lives of Duchenne patients,” said Debra Miller,
CEO and Founder of Cure Duchenne that provided the initial seed funding
for Exonics. “We are delighted that the talented scientists at Vertex
and Exonics will work together to advance these promising gene editing
treatments for Duchenne and other neuromuscular diseases.”
About Vertex’s Collaboration with CRISPR Therapeutics
Under
the terms of this strategic collaboration and license agreement, Vertex
will pay $175 million upfront for the exclusive worldwide rights to
CRISPR Therapeutics’ existing and future intellectual property including
foundational CRISPR/Cas9 technology, novel endonucleases, single and
double cut guide RNAs, and AAV vectors for DMD and DM1 gene editing
products.
For the DMD program, Vertex is responsible for all research,
development, manufacturing, and commercialization activities and all
related costs. For the DM1 program, Vertex and CRISPR will share
research costs for specified guide RNA research to be conducted by
CRISPR, and Vertex is responsible for all other research, development,
manufacturing, and commercialization costs.
CRISPR Therapeutics is eligible to receive payments of up to $1 billion
inclusive of the upfront and potential future payments based upon the
successful achievement of specified research, development, regulatory,
and commercial milestones for the DMD and DM1 programs. In addition,
Vertex will pay tiered royalties on future net sales on any products
that may result from this collaboration. At IND filing, CRISPR has the
option to forego the DM1 milestones and royalties to co-develop and
co-commercialize all DM1 products globally.
The closing of this transaction will be subject to certain conditions,
including the expiration of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act. The companies anticipate
the transaction will close in the third quarter of 2019.
About Vertex’s Acquisition of Exonics Therapeutics
Exonics
Therapeutics is developing gene editing therapies to treat patients with
DMD and other severe genetic neuromuscular diseases and brings to Vertex
intellectual property, technology, and scientific expertise in gene
editing therapies for these serious diseases. In multiple small and
large animal DMD preclinical models, Exonics has used SingleCut CRISPR
to genetically repair and restore dystrophin, the key protein missing in
children with DMD.
Exonics’ technology is licensed from UT Southwestern Medical Center and
is based on the research of Dr. Olson. Dr. Olson will continue in his
role as Exonics’ chief science advisor and provide oversight and
guidance on the research and development of transformative gene editing
therapies.
Under the terms of the acquisition, Vertex will acquire all outstanding
shares of Exonics, which will become a separate wholly-owned subsidiary
of Vertex. Exonics equity holders are eligible to receive payments of
approximately $1 billion, including $245 million upfront and potential
future payments based primarily upon the successful achievement of
specified development and regulatory milestones for the DMD and DM1
programs.
The closing of this transaction will be subject to certain conditions,
including the expiration of the waiting period under the
Hart-Scott-Rodino Antitrust Improvements Act and other customary
conditions. The companies anticipate the acquisition will close in the
third quarter of 2019.
About Vertex’s Scientific Leadership Expansion
Vertex today
announced the appointment of Dr. John T. Gray as Senior Vice President,
Genetic Therapies effective June 17, 2019.
With more than twenty-five years in academic and industry settings, John
is a proven leader in the genetic therapies space with experience in
both the scientific and manufacturing sides of product development. His
capabilities and expertise are an ideal fit with Vertex’s strategy to
bring the multi-faceted components of genetic therapies together and to
advance the science of genetic therapies, such that the Vertex genetic
therapies platform offers the best of all this emerging approach has to
offer.
John previously served as Chief Scientific Officer and Senior Vice
President at Audentes Therapeutics where he and his team focused on rAAV
gene therapy for neuromuscular and liver disorders. John has a B.A. in
Biochemistry from the University of California, Berkeley and a Ph.D. in
Biochemistry from the University of Colorado, Boulder and was a
postdoctoral Scientist at the Howard Hughes Medical Institute and Pfizer
Central Research.
About Vertex’s New Genetic Therapies Research Site
Vertex
will establish a new genetic therapies research site in the Boston area
where research programs, as well as vector development and clinical
manufacturing for genetic therapies, including DMD and DM1 programs,
will be conducted.
About Vertex
Vertex is a global biotechnology company that
invests in scientific innovation to create transformative medicines for
people with serious and life-threatening diseases. In addition to
clinical development programs in CF, Vertex has more than a dozen
ongoing research programs focused on the underlying mechanisms of other
serious diseases.
Founded in 1989 in Cambridge, Mass., Vertex’s headquarters is now
located in Boston’s Innovation District. Today, the company has research
and development sites and commercial offices in the United States,
Europe, Canada, Australia and Latin America. Vertex is consistently
recognized as one of the industry’s top places to work, including being
named to Science magazine’s Top Employers in the life sciences
ranking for nine years in a row.
For additional information and the latest updates from the company,
please visit www.vrtx.com.
Vertex Special Note Regarding Forward-Looking Statements
This
press release contains forward-looking statements as defined in the
Private Securities Litigation Reform Act of 1995, including, without
limitation, Dr. Leiden’s statements in the fourth paragraph of the press
release, Dr. Kulkarni’s statements in the fifth paragraph of the press
release, Dr. Olson’s statements in the sixth paragraph of the press
release, Ms. Miller’s statements in the seventh paragraph of the press
release and statements regarding the timing of the potential closing of
the transaction, future activities of the parties pursuant to the
collaboration and the potential benefits of the acquisition. While
Vertex believes the forward-looking statements contained in this press
release are accurate, these forward-looking statements represent
Vertex’s beliefs only as of the date of this press release and there are
a number of factors that could cause actual events or results to differ
materially from those indicated by such forward-looking statements.
Those risks and uncertainties include, among other things, both
transactions are subject to certain conditions, including the expiration
of the waiting period under the Hart-Scott-Rodino Antitrust Improvements
Act, Vertex may not realize the potential benefits of the collaboration
or acquisition, and the other risks listed under Risk Factors in
Vertex’s annual report and quarterly reports filed with the Securities
and Exchange Commission and available through the company’s website at www.vrtx.com.
Vertex disclaims any obligation to update the information contained in
this press release as new information becomes available.
About CRISPR Therapeutics
CRISPR Therapeutics is a leading
gene editing company focused on developing transformative gene-based
medicines for serious diseases using its proprietary CRISPR/Cas9
platform. CRISPR/Cas9 is a revolutionary gene editing technology that
allows for precise, directed changes to genomic DNA. CRISPR Therapeutics
has established a portfolio of therapeutic programs across a broad range
of disease areas including hemoglobinopathies, oncology, regenerative
medicine and rare diseases. To accelerate and expand its efforts, CRISPR
Therapeutics has established strategic collaborations with leading
companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc.
CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its
wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D
operations based in Cambridge, Massachusetts, and business offices in
London, United Kingdom. For more information, please visit www.crisprtx.com.
CRISPR Forward-Looking Statement
This press release may
contain a number of “forward-looking statements” within the meaning of
the Private Securities Litigation Reform Act of 1995, as amended,
including statements regarding CRISPR Therapeutics’ expectations about
any or all of the following: (i) clinical trials (including, without
limitation, the timing of filing of clinical trial applications and
INDs, any approvals thereof and the timing of commencement of clinical
trials), development timelines and discussions with regulatory
authorities related to product candidates under development by CRISPR
Therapeutics and its collaborators; (ii) the number of patients that
will be evaluated, the anticipated date by which enrollment will be
completed and the data that will be generated by ongoing and planned
clinical trials, and the ability to use that data for the design and
initiation of further clinical trials; (iii) the scope and timing of
ongoing and potential future clinical trials; (iv) the intellectual
property coverage and positions of CRISPR Therapeutics, its licensors
and third parties; (v) the sufficiency of CRISPR Therapeutics’ cash
resources; and (vi) the therapeutic value, development, and commercial
potential of CRISPR/Cas9 gene editing technologies and therapies.
Without limiting the foregoing, the words “believes,” “anticipates,”
“plans,” “expects” and similar expressions are intended to identify
forward-looking statements. You are cautioned that forward-looking
statements are inherently uncertain. Although CRISPR Therapeutics
believes that such statements are based on reasonable assumptions within
the bounds of its knowledge of its business and operations,
forward-looking statements are neither promises nor guarantees and they
are necessarily subject to a high degree of uncertainty and risk. Actual
performance and results may differ materially from those projected or
suggested in the forward-looking statements due to various risks and
uncertainties. These risks and uncertainties include, among others: the
outcomes for each CRISPR Therapeutics’ planned clinical trials and
studies may not be favorable; that one or more of CRISPR Therapeutics’
internal or external product candidate programs will not proceed as
planned for technical, scientific or commercial reasons; that future
competitive or other market factors may adversely affect the commercial
potential for CRISPR Therapeutics’ product candidates; uncertainties
inherent in the initiation and completion of preclinical studies for
CRISPR Therapeutics’ product candidates; availability and timing of
results from preclinical studies; whether results from a preclinical
trial will be predictive of future results of the future trials;
uncertainties about regulatory approvals to conduct trials or to market
products; uncertainties regarding the intellectual property protection
for CRISPR Therapeutics’ technology and intellectual property belonging
to third parties; and those risks and uncertainties described under the
heading “Risk Factors” in CRISPR Therapeutics’ most recent annual report
on Form 10-K, and in any other subsequent filings made by CRISPR
Therapeutics with the U.S. Securities and Exchange Commission, which are
available on the SEC’s website at www.sec.gov.
Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of the
date they are made. CRISPR Therapeutics disclaims any obligation or
undertaking to update or revise any forward-looking statements contained
in this press release, other than to the extent required by law.
About Exonics Therapeutics
Exonics Therapeutics is
developing gene editing therapies to treat patients with Duchenne
muscular dystrophy and other severe genetic neuromuscular diseases. In
multiple Duchenne preclinical models, Exonics has used SingleCut CRISPR
to genetically repair and restore dystrophin, the key protein missing in
children with Duchenne. Exonics is initially focused on repairing
mutations that cause Duchenne in order to develop a therapy to treat
many children with the devastating disease, for which there is no cure.
Exonics’ technology is licensed from UT Southwestern Medical Center and
is based on the research of Eric Olson, Ph.D., Exonics’ founder and
chief science advisor. Exonics is located in Watertown, Mass. For more
information, please visit www.exonicstx.com.
(VRTX-GEN)
Contacts
Vertex Investor Contacts:
Michael Partridge, 617-341-6108
or
Eric
Rojas, 617-961-7205
or
Zach Barber, 617-341-6470
Vertex Media Contact:
Heather Nichols
617-341-6992
mediainfo@vrtx.com
CRISPR Investor Contact:
Susan Kim
+1 617-307-7503
susan.kim@crisprtx.com
CRISPR Media Contact:
Jennifer Paganelli
WCG on behalf
of CRISPR
+1 347-658-8290
jpaganelli@wcgworld.com
Exonics Media Contact:
Heather Anderson
6 Degrees
980-938-0260
handerson@6degreespr.com